A citation-based method for searching scientific literature

Eniko Barczi, Livia Starobinski, Abigel Kolonics-Farkas, Noemi Eszes, Aniko Bohacs, Martina Vasakova, Karel Hejduk, Veronika Müller. Adv Ther 2019
Times Cited: 6







List of co-cited articles
55 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
83

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis.
Gareth Hughes, Hannah Toellner, Helen Morris, Colm Leonard, Nazia Chaudhuri. J Clin Med 2016
96
66

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.
Sophie V Fletcher, Mark G Jones, Elizabeth A Renzoni, Helen Parfrey, Rachel K Hoyles, Katherine Spinks, Maria Kokosi, Apollinaris Kwok, Chris Warburton, Vanessa Titmuss,[...]. ERJ Open Res 2018
13
66

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
104
66

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
66

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
641
66

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
50

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
Hee-Young Yoon, Sojung Park, Dong Soon Kim, Jin Woo Song. Respir Res 2018
35
50

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
78
50

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Francesco Bonella, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus Keller, Martin J Kohlhaeufl, Joachim Müller-Quernheim, Katrin Milger, Antje Prasse. Respiration 2016
40
50

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events.
Elisabeth Bendstrup, Wim Wuyts, Tiago Alfaro, Nazia Chaudhuri, Robin Cornelissen, Michael Kreuter, Kirsten Melgaard Nielsen, Anna-Marie B Münster, Marjukka Myllärniemi, Claudia Ravaglia,[...]. Respiration 2019
21
50

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA.
Imre Noth, David Oelberg, Manika Kaul, Craig S Conoscenti, Ganesh Raghu. Eur Respir J 2018
19
50

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.
Sergio Harari, Antonella Caminati, Venerino Poletti, Marco Confalonieri, Stefano Gasparini, Donato Lacedonia, Fabrizio Luppi, Alberto Pesci, Alfredo Sebastiani, Paolo Spagnolo,[...]. Respiration 2018
29
50

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Tamera Corte, Francesco Bonella, Bruno Crestani, Maurits G Demedts, Luca Richeldi, Carl Coeck, Katy Pelling, Manuel Quaresma, Joseph A Lasky. Respir Res 2015
72
50

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Toby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moisés Selman, Klaus B Rohr, Andreas Michael, Carina Ittrich,[...]. Lancet Respir Med 2019
29
50

Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.
Michael Kreuter, Svenja Ehlers-Tenenbaum, Karin Palmowski, Jacques Bruhwyler, Ute Oltmanns, Thomas Muley, Claus Peter Heussel, Arne Warth, Martin Kolb, Felix J F Herth. PLoS One 2016
148
50

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
50

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Jonathan A Galli, Aloknath Pandya, Michelle Vega-Olivo, Chandra Dass, Huaqing Zhao, Gerard J Criner. Respirology 2017
80
50

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres.
Hannah Toellner, G Hughes, W Beswick, M G Crooks, C Donaldson, I Forrest, S P Hart, C Leonard, M Major, A J Simpson,[...]. Clin Transl Med 2017
20
50

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Eva Brunnemer, Julia Wälscher, Svenja Tenenbaum, Julia Hausmanns, Karen Schulze, Marianne Seiter, Claus Peter Heussel, Arne Warth, Felix J F Herth, Michael Kreuter. Respiration 2018
40
50

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
985
33

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.
Toby M Maher, Jeffrey J Swigris, Michael Kreuter, Marlies Wijsenbeek, Nicola Cassidy, Lucy Ireland, Judit Axmann, Steven D Nathan. Respiration 2018
27
33


Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.
Harold R Collard, Luca Richeldi, Dong Soon Kim, Hiroyuki Taniguchi, Inga Tschoepe, Maurizio Luisetti, Jesse Roman, Gregory Tino, Rozsa Schlenker-Herceg, Christoph Hallmann,[...]. Eur Respir J 2017
71
33

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials.
Jeffrey J Swigris, Hilary Wilson, Dirk Esser, Craig S Conoscenti, Wibke Stansen, Nancy Kline Leidy, Kevin K Brown. BMJ Open Respir Res 2018
29
33

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
E Bargagli, C Piccioli, E Rosi, E Torricelli, L Turi, E Piccioli, M Pistolesi, K Ferrari, L Voltolini. Pulmonology 2019
22
33


Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF.
Katrin Milger, Nikolaus Kneidinger, Claus Neurohr, Frank Reichenberger, Jürgen Behr. Eur Respir J 2015
27
33

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R Collard, Inga Tschoepe, Susanne Stowasser, Arata Azuma. Am J Respir Crit Care Med 2016
151
33

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
103
33

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
Martin Kolb, Luca Richeldi, Jürgen Behr, Toby M Maher, Wenbo Tang, Susanne Stowasser, Christoph Hallmann, Roland M du Bois. Thorax 2017
115
33

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.
Andreas Guenther, Ekaterina Krauss, Silke Tello, Jasmin Wagner, Bettina Paul, Stefan Kuhn, Olga Maurer, Sabine Heinemann, Ulrich Costabel, María Asunción Nieto Barbero,[...]. Respir Res 2018
107
33

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Sebastiano Emanuele Torrisi, Nicolas Kahn, Julia Wälscher, Nilab Sarmand, Markus Polke, Kehler Lars, Monika Eichinger, Claus Peter Heussel, Stefano Palmucci, Francesca Maria Sambataro,[...]. BMC Pulm Med 2019
11
33

Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.
Luca Richeldi, Bruno Crestani, Arata Azuma, Martin Kolb, Moisés Selman, Wibke Stansen, Manuel Quaresma, Susanne Stowasser, Vincent Cottin. Respir Med 2019
9
33

A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world.
Masayuki Nakamura, Masaki Okamoto, Kiminori Fujimoto, Tomohiro Ebata, Masaki Tominaga, Takashi Nouno, Yoshiaki Zaizen, Shinjiro Kaieda, Tohru Tsuda, Tomotaka Kawayama,[...]. Ann Transl Med 2019
8
33

South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Shaney L Barratt, Sarah Mulholland, Khaled Al Jbour, Henry Steer, Markus Gutsche, Noeleen Foley, Rajiv Srivastava, Charles Sharp, Huzaifa I Adamali. Front Pharmacol 2018
17
33

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.
Kevin K Brown, Kevin R Flaherty, Vincent Cottin, Ganesh Raghu, Yoshikazu Inoue, Arata Azuma, John T Huggins, Luca Richeldi, Susanne Stowasser, Wibke Stansen,[...]. Respir Med 2019
16
33

Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data.
Joo Heung Yoon, Mehdi Nouraie, Xiaoping Chen, Richard H Zou, Jacobo Sellares, Kristen L Veraldi, Jared Chiarchiaro, Kathleen Lindell, David O Wilson, Naftali Kaminski,[...]. Respir Res 2018
19
33

Lung cancer in patients with idiopathic pulmonary fibrosis.
Theodoros Karampitsakos, Vasilios Tzilas, Rodoula Tringidou, Paschalis Steiropoulos, Vasilis Aidinis, Spyros A Papiris, Demosthenes Bouros, Argyris Tzouvelekis. Pulm Pharmacol Ther 2017
68
33

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
Luca Richeldi, Francesco Varone, Miguel Bergna, Joao de Andrade, Jeremy Falk, Robert Hallowell, Stéphane Jouneau, Yasuhiro Kondoh, Lee Morrow, Winfried Randerath,[...]. Eur Respir Rev 2018
39
33

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
33

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
404
33

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.
Michael Kreuter, Jeff Swigris, David Pittrow, Silke Geier, Jens Klotsche, Antje Prasse, Hubert Wirtz, Dirk Koschel, Stefan Andreas, Martin Claussen,[...]. Respir Res 2017
79
33

The therapy of idiopathic pulmonary fibrosis: what is next?
Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, Nicolas Kahn, Veronika Müller, Michael Kreuter. Eur Respir Rev 2019
54
33

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.
Ulrich Costabel, Jürgen Behr, Bruno Crestani, Wibke Stansen, Rozsa Schlenker-Herceg, Susanne Stowasser, Ganesh Raghu. Respir Res 2018
20
33

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
430
33

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.
Argyrios Tzouvelekis, Theodoros Karampitsakos, Maria Kontou, Andreas Granitsas, Ioanna Malliou, Aris Anagnostopoulos, Paschalis Ntolios, Vasilios Tzilas, Evangelos Bouros, Paschalis Steiropoulos,[...]. Pulm Pharmacol Ther 2018
34
33

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Helen E Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M A Hopkins, Yuben Moodley, Paul N Reynolds, Sally Chapman, E Haydn Walters, Christopher Zappala,[...]. Eur Respir J 2017
100
33

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
Lisa Lancaster, Bruno Crestani, Paul Hernandez, Yoshikazu Inoue, Daniel Wachtlin, Lazaro Loaiza, Manuel Quaresma, Susanne Stowasser, Luca Richeldi. BMJ Open Respir Res 2019
52
33

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study.
Mitsuhiro Abe, Kenji Tsushima, Masashi Sakayori, Kenichi Suzuki, Jun Ikari, Jiro Terada, Koichiro Tatsumi. Drug Des Devel Ther 2018
12
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.